Incidence of intestinal & extra-intestinal cancers among individuals with Crohn’s disease in northern India

Sep 21, 2026

Uploaded by Rowan

Crohn’s disease is linked to higher malignancy risk due to disease behavior and immunosuppressant use, yet CD-related cancer burden is scarcely reported from Asia. This retrospective study followed Crohn’s disease patients at All India Institute of Medical Sciences, New Delhi, from 2005 to 2021, using standardized incidence ratio to compare malignancy risk with the general population. Among 952 participants, overall malignancy incidence was 1.05% with a 10.45-fold increased risk.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Background & objectives

Methods

Results

Interpretation & conclusions

Key words

Indian J Med Res 160, July 2024, pp 61-69 DOI: 10.25259/ijmr_ 1722_23 | Quick Response Code: | | --- | | | Incidence of intestinal & extra-intestinal cancers among individuals with Crohn’s disease in northern India Parth Sharma\#,*, Varad Putambekar\#,†, Peeyush Kumar1, David Mathew Thomas1, Sudheer K. Vuyyuru 1, Bhaskar Kante1, Sandeep Kumar Mundhra1, Raju Sharma2, Nihar Ranjan Dash3, Govind Makharia1, Saurabh Kedia1 & Vineet Ahuja1 Departments of 1 Gastroenterology and Human Nutrition, 2Radiology, & 3 Gastrointestinal Surgery, \#All India Institute of Medical Sciences, New Delhi, India Received August 28, 2023 Background & objectives: Crohn’s disease (CD) is associated with a higher risk of malignancy, which is attributed to disease behaviour and the usage of immunosuppressants. The burden of malignancy in CD is scarcely reported from Asia. We report real-world data on CD-related malignancy from a northern Indian cohort. Methods: This retrospective analysis included individuals with CD who were followed up at the All India Institute of Medical Sciences, New Delhi, from 2005 to 2021. The standardized incidence ratio (SIR) was used to calculate the relative risk of malignancy in CD affected individuals compared to the general population. Results: In this study, 952 study participants were included, with a mean age at diagnosis of 36.9±15.11 yr; 61.1 per cent were male. The median follow-up duration was 34 months [IQR (interquartile range): 19-73]. Most study participants received steroids (76.7%), immunomodulators (68.7%), or anti-TNF therapy (10.8%). The overall incidence of malignancy was 1.05 per cent, indicating a 10.45 times higher risk in CD [SIR: 10.45; 95% Confidence interval (CI):4.98-17.96]. Eight out of 826, 1 of 106 and 1 of 25 study participants developed malignancy in the first, second and third decades, respectively. The cumulative risk of malignancy was 2.7, 5.5, and 13.4 per cent in the first, second, and third decades, respectively. Regarding bowel malignancies, one study participant each developed ileocaecal adenocarcinoma, anorectal adenocarcinoma, malignant rectal fibrous histiocytoma, and gastric adenocarcinoma. Extraintestinal malignancies included single cases each of follicular neoplasia of the thyroid, neuroendocrine tumour of the pancreatic tail, breast cancer, hepatocellular cancer, oral cancer, and prostate cancer. No cases of lymphoma or skin malignancy were reported. Interpretation & conclusions: At 30 yr, the cumulative risk of malignancy among Indian CD-affected individuals was 13.4 per cent, with a SIR of 10.45 (95% CI: 4.98- 17.96). The risk increased with increasing age at disease onset and duration. Key words Malignancy-Crohn’s disease-intestinal cancer-extra-intestinal cancer Present address: *Department of Internal Medicine, University of Missouri-Kansas City, Missouri, U. S.A; †Center of Global Health Research, Nuffield Department of Medicine, University of Oxford, United Kingdom © 2024 Indian Journal of Medical Research, published by Scientific Scholar for Director-General, Indian Council of Medical Research This open access publication is protected under CC-BY-NC-SA 4.0 62 INDIAN J MED RES, JULY 2024 Rudolf Virchow, in 1863, linked inflammation with cancer when he observed leukocytes in the cancer tissue1. Following this astute observation, numerous inflammatory conditions have been causally associated with cancers such as Helicobacter pylori-associated gastritis (gastric cancer), viral hepatitis (hepatocellular cancer), and chronic pancreatitis (carcinoma pancreas)2. Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory condition of the gastrointestinal tract. In India and other nations in the Asia-Pacific areas, the prevalence of IBD is rapidly rising3,4 . Asthe burden increases and more efficient treatment alternatives become available, clinici

FAQs

What was the main objective of the study?

To report real-world data on Crohn’s disease–related malignancy in a northern Indian cohort and quantify the relative risk versus the general population.

How was malignancy risk in Crohn’s disease patients measured?

The study used standardized incidence ratio (SIR) to calculate relative risk of malignancy in Crohn’s disease affected individuals compared with the general population.

What were the key findings regarding malignancy incidence and risk?

Among 952 participants, the overall malignancy incidence was 1.05%, corresponding to an SIR of 10.45 (95% CI: 4.98–17.96), with risk increasing with age at disease onset and disease duration.

Sep 21, 2026

Uploaded by Rowan